Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial

BACKGROUND: In intermediate-risk non-muscle invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patients receive this adjuvant chemotherapeutic instilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Seiler, Roland, Egger, Martin, De Menna, Marta, Wehrli, Saskia, Minoli, Martina, Radić, Martina, Lyatoshinsky, Pavel, Hösli, Raphael, Blarer, Jennifer, Abt, Dominik, Kruithof-de Julio, Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176900/
https://www.ncbi.nlm.nih.gov/pubmed/37170307
http://dx.doi.org/10.1186/s12894-023-01262-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176900/
https://www.ncbi.nlm.nih.gov/pubmed/37170307
http://dx.doi.org/10.1186/s12894-023-01262-1

Ejemplares similares